Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 12 | 2025 | 209 | 2.220 |
Why?
|
| Angiogenesis Inhibitors | 11 | 2025 | 291 | 1.940 |
Why?
|
| Ranibizumab | 5 | 2025 | 19 | 1.920 |
Why?
|
| Intravitreal Injections | 16 | 2025 | 83 | 1.490 |
Why?
|
| Wet Macular Degeneration | 5 | 2024 | 22 | 1.450 |
Why?
|
| Macular Degeneration | 6 | 2025 | 50 | 1.290 |
Why?
|
| Tomography, Optical Coherence | 8 | 2025 | 131 | 1.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2025 | 398 | 1.190 |
Why?
|
| Retinal Diseases | 4 | 2024 | 84 | 1.140 |
Why?
|
| Subretinal Fluid | 2 | 2024 | 4 | 1.100 |
Why?
|
| Macular Edema | 5 | 2025 | 46 | 1.030 |
Why?
|
| Drug Delivery Systems | 2 | 2025 | 194 | 0.980 |
Why?
|
| Retina | 2 | 2024 | 215 | 0.800 |
Why?
|
| Geographic Atrophy | 3 | 2025 | 10 | 0.640 |
Why?
|
| Eye Diseases | 1 | 2020 | 58 | 0.620 |
Why?
|
| Ophthalmology | 1 | 2020 | 46 | 0.610 |
Why?
|
| Diabetic Retinopathy | 3 | 2025 | 82 | 0.570 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 32 | 0.510 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2017 | 66 | 0.510 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 37 | 0.500 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 5 | 2024 | 62 | 0.490 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 452 | 0.460 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2024 | 555 | 0.390 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1103 | 0.390 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 1001 | 0.380 |
Why?
|
| Chorioretinitis | 1 | 2012 | 7 | 0.360 |
Why?
|
| West Nile Fever | 1 | 2012 | 19 | 0.360 |
Why?
|
| Fluorescein Angiography | 4 | 2025 | 83 | 0.360 |
Why?
|
| Treatment Outcome | 10 | 2025 | 9099 | 0.320 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2008 | 2 | 0.280 |
Why?
|
| Telangiectasis | 1 | 2008 | 8 | 0.280 |
Why?
|
| Glaucoma, Neovascular | 1 | 2008 | 5 | 0.280 |
Why?
|
| Facial Muscles | 1 | 2008 | 24 | 0.280 |
Why?
|
| Muscle Hypotonia | 1 | 2008 | 48 | 0.270 |
Why?
|
| Retinal Vessels | 1 | 2008 | 51 | 0.270 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2025 | 86 | 0.260 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 767 | 0.230 |
Why?
|
| Humans | 24 | 2025 | 93515 | 0.230 |
Why?
|
| High-Temperature Requirement A Serine Peptidase 1 | 1 | 2025 | 2 | 0.230 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 7061 | 0.220 |
Why?
|
| Aged | 11 | 2025 | 20434 | 0.220 |
Why?
|
| Choroidal Neovascularization | 2 | 2024 | 23 | 0.220 |
Why?
|
| Complement Inactivating Agents | 1 | 2023 | 7 | 0.200 |
Why?
|
| Aptamers, Nucleotide | 1 | 2023 | 26 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 3830 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2022 | 55 | 0.180 |
Why?
|
| Middle Aged | 11 | 2025 | 27573 | 0.180 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 373 | 0.170 |
Why?
|
| Male | 13 | 2025 | 44557 | 0.170 |
Why?
|
| Retinal Perforations | 1 | 2020 | 14 | 0.170 |
Why?
|
| Female | 14 | 2025 | 48702 | 0.170 |
Why?
|
| Vitrectomy | 1 | 2020 | 48 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 262 | 0.150 |
Why?
|
| Disease Management | 1 | 2020 | 358 | 0.140 |
Why?
|
| Actinomyces | 1 | 2017 | 5 | 0.130 |
Why?
|
| Bevacizumab | 2 | 2024 | 256 | 0.130 |
Why?
|
| Actinomycosis | 1 | 2017 | 13 | 0.130 |
Why?
|
| Eye Infections, Bacterial | 1 | 2017 | 12 | 0.130 |
Why?
|
| Endophthalmitis | 1 | 2017 | 19 | 0.130 |
Why?
|
| Algorithms | 1 | 2024 | 1953 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2024 | 1729 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 2 | 2006 | 174 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1546 | 0.100 |
Why?
|
| Propylene Glycols | 1 | 2013 | 31 | 0.100 |
Why?
|
| Sphingosine | 1 | 2013 | 73 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2024 | 10164 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 261 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2017 | 3829 | 0.080 |
Why?
|
| Eye Enucleation | 1 | 2008 | 7 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2008 | 46 | 0.070 |
Why?
|
| Intraocular Pressure | 1 | 2008 | 62 | 0.070 |
Why?
|
| Laser Coagulation | 1 | 2008 | 55 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 990 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 214 | 0.070 |
Why?
|
| Trigeminal Ganglion | 1 | 2006 | 15 | 0.060 |
Why?
|
| Nervous System | 1 | 2006 | 92 | 0.060 |
Why?
|
| Herpes Simplex | 1 | 2006 | 79 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2025 | 159 | 0.050 |
Why?
|
| Keratitis, Herpetic | 1 | 2004 | 10 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2004 | 74 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 4560 | 0.050 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 38 | 0.050 |
Why?
|
| Eye | 1 | 2004 | 109 | 0.050 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2024 | 26 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2023 | 37 | 0.050 |
Why?
|
| Herpesvirus 1, Human | 1 | 2004 | 212 | 0.050 |
Why?
|
| Fluocinolone Acetonide | 1 | 2022 | 8 | 0.050 |
Why?
|
| Drug Implants | 1 | 2022 | 37 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2022 | 150 | 0.040 |
Why?
|
| Steroids | 1 | 2022 | 168 | 0.040 |
Why?
|
| Patient Selection | 1 | 2024 | 690 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1914 | 0.040 |
Why?
|
| Indoles | 1 | 2022 | 303 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 485 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2022 | 362 | 0.040 |
Why?
|
| United States | 2 | 2024 | 7622 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2022 | 384 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 416 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1847 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 1050 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 2391 | 0.030 |
Why?
|
| Nectins | 2 | 2006 | 8 | 0.030 |
Why?
|
| Time Factors | 1 | 2024 | 5410 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1448 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2006 | 1101 | 0.020 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2013 | 31 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 657 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 2006 | 81 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 293 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2004 | 248 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1799 | 0.010 |
Why?
|
| Mice | 2 | 2006 | 12269 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 28155 | 0.010 |
Why?
|